367 related articles for article (PubMed ID: 16758424)
1. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
[TBL] [Abstract][Full Text] [Related]
2. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
3. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
4. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
[TBL] [Abstract][Full Text] [Related]
5. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
6. [HLA-B*5701 and abacavir hypersensitivity reaction].
Servonnet A; Leclercq E; Delacour H; Ceppa F
Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
[TBL] [Abstract][Full Text] [Related]
8. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
Young B; Squires K; Patel P; Dejesus E; Bellos N; Berger D; Sutherland-Phillips DH; Liao Q; Shaefer M; Wannamaker P
AIDS; 2008 Aug; 22(13):1673-5. PubMed ID: 18670229
[TBL] [Abstract][Full Text] [Related]
9. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
10. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
Phillips EJ
Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
[No Abstract] [Full Text] [Related]
11. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
12. Current trends in screening across ethnicities for hypersensitivity to abacavir.
Rodriguez-Nóvoa S; Soriano V
Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
[TBL] [Abstract][Full Text] [Related]
13. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
[TBL] [Abstract][Full Text] [Related]
14. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
[TBL] [Abstract][Full Text] [Related]
15. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
[TBL] [Abstract][Full Text] [Related]
16. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
[TBL] [Abstract][Full Text] [Related]
17. Abacavir hypersensitivity reaction.
AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
[No Abstract] [Full Text] [Related]
18. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
Kapoor S
AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
[No Abstract] [Full Text] [Related]
19. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
[TBL] [Abstract][Full Text] [Related]
20. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
